Suguru Okami

Dr. Suguru Okami


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
KBKåre Inge Birkeland
Kåre Inge Birkeland
JBJohan Bodegard
Johan Bodegard
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
ANAnna Norhammar
Anna Norhammar
HHHermann Haller
Hermann Haller
TKTakashi Kadowaki
Takashi Kadowaki
Aims: To examine the manifestation of cardiovascular or renal disease (CVRD) in patients with type 2 diabetes (T2D) initially free from CVRD as well as the mortality risks associated with these diseases. Methods: Patients free from CVRD were identified from healthcare records in England, Germany, Japan, the Netherlands, Norway and Sweden at a fixed date. CVRD manifestation was defined by first diagnosis of cardiorenal disease, or a stroke, myocardial infarction (MI) or peripheral artery disease (PAD) event. The mortality risk associated with single CVRD history of heart failure (HF), chronic kidney disease (CKD), MI, stroke or PAD was compared with that associated with CVRD‐free status. Results: Of 1 177 896 patients with T2D, 772 336 (66%) were CVRD‐free and followed for a mean of 4.5 years. A total of 137 081 patients (18%) developed a first CVRD manifestation, represented by CKD (36%), HF (24%), stroke (16%), MI (14%) and PAD (10%). HF or CKD was associated with increased cardiovascular and all‐cause mortality risk: hazard ratio (HR) 2.02 (95% confidence interval [CI] 1.75–2.33) and HR 2.05 (95% CI 1.82–2.32), respectively. HF and CKD were separately associated with significantly increased mortality risks, and the combination was associated with the highest cardiovascular and all‐cause mortality risk: HRs 3.91 (95% CI 3.02–5.07) and 3.14 (95% CI 2.90–3.40), respectively. Conclusion: In a large multinational study of >750 000 CVRD‐free patients with T2D, HF and CKD were consistently the most frequent first cardiovascular disease manifestations and were also associated with increased mortality risks. These novel findings show these cardiorenal diseases to be important and serious complications requiring improved preventive strategies.

7 September 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
KBKåre Inge Birkeland
Kåre Inge Birkeland
JBJohan Bodegard
Johan Bodegard
ABAmitava Banerjee
Amitava Banerjee
DKDae Jung Kim
Dae Jung Kim
ANAnna Norhammar
Anna Norhammar
TKTakashi Kadowaki
Takashi Kadowaki
Aims: We compared the new use of sodium‐glucose cotransporter‐2 inhibitor (SGLT2i) versus dipeptidyl peptidase‐4 inhibitor (DPP4i) and the risk of cardiorenal disease, heart failure (HF) or chronic kidney disease (CKD), in patients with type 2 diabetes without a history of prevalent cardiovascular and renal disease, defined as cardiovascular and renal disease (CVRD) free, managed in routine clinical practice. Materials and methods: In this observational cohort study, patients were identified from electronic health records from England, Germany, Japan, Norway, South Korea and Sweden, during 2012‐2018. In total, 1 006 577 CVRD‐free new users of SGLT2i or DPP4i were propensity score matched 1:1. Unadjusted Cox regression was used to estimate hazard ratios (HRs) for outcomes: cardiorenal disease, HF, CKD, stroke, myocardial infarction (MI), cardiovascular and all‐cause mortality. Results: Baseline characteristics were well balanced between the treatment groups (n = 105 130 in each group) with total follow‐up of 187 955 patient years. Patients had a mean age of 56 years, 43% were women and they were indexed between 2013 and 2018. The most commonly used agents were dapagliflozin (91.7% of exposure time) and sitagliptin/linagliptin (55.0%), in the SGLT2i and DPP4i, groups, respectively. SGLT2i was associated with lower risk of cardiorenal disease, HF, CKD, all‐cause and cardiovascular mortality; HR (95% confidence interval), 0.56 (0.42‐0.74), 0.71 (0.59‐0.86), 0.44 (0.28‐0.69), 0.67 (0.59‐0.77), and 0.61 (0.44‐0.85), respectively. No differences were observed for stroke [0.87 (0.69‐1.09)] and MI [0.94 (0.80‐1.11)]. Conclusion: In this multinational observational study, SGLT2i was associated with a lower risk of HF and CKD versus DPP4i in patients with type 2 diabetes otherwise free from both cardiovascular and renal disease.

9 April 2021 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
SKShun Kohsaka
Shun Kohsaka
NMNaru Morita
Naru Morita
SOSuguru Okami
Suguru Okami
YKYoko Kidani
Yoko Kidani
TYToshitaka Yajima
Toshitaka Yajima
With the widespread use of electronic medical records and administrative claims databases, analytic results from so‐called real‐world data have become increasingly important in healthcare decision‐making. Diabetes mellitus is a heterogeneous condition that involves a broad spectrum of patients. Real‐world database studies have been recognised as a powerful tool to understand the impact of current practices on clinical courses and outcomes, such as long‐term glucose control, development of microvascular or macro‐vascular diseases, and mortality. Diabetes is also a major global health issue and poses a significant social and economic burden worldwide. Therefore, it is critical to understand the epidemiology, clinical course, treatment reality, and long‐term outcomes of diabetes to determine realistic solutions to a variety of disease‐related issues that we are facing. In the present review, we summarise the healthcare system and large‐scale databases currently available in Japan, introduce the results from recent database studies involving Japanese patients with diabetes, and discuss future opportunities and challenges for the use of databases in the management of diabetes.

19 April 2022 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
ANAnna Norhammar
Anna Norhammar
JBJohan Bodegard
Johan Bodegard
Jan W. ErikssonJan W. Eriksson
Jan W. Eriksson
HHHermann Haller
Hermann Haller
GLGerard Linssen
Gerard Linssen
CICaReMe Cardiorenal Investigators
CaReMe Cardiorenal Investigators
Aim: To examine how the development of cardiovascular and renal disease (CVRD) translates to hospital healthcare costs in individuals with type 2 diabetes (T2D) initially free from CVRD. Methods: Data were obtained from the digital healthcare systems of 12 nations using a prespecified protocol. A fixed country‐specific index date of 1 January was chosen to secure sufficient cohort disease history and maximal follow‐up, varying between each nation from 2006 to 2017. At index, all individuals were free from any diagnoses of CVRD (including heart failure [HF], chronic kidney disease [CKD], coronary ischaemic disease, stroke, myocardial infarction [MI], or peripheral artery disease [PAD]). Outcomes during follow‐up were hospital visits for CKD, HF, MI, stroke, and PAD. Hospital healthcare costs obtained from six countries, representing 68% of the total study population, were cumulatively summarized for CVRD events occurring during follow‐up. Results: In total, 1.2 million CVRD‐free individuals with T2D were identified and followed for 4.5 years (mean), that is, 4.9 million patient‐years. The proportion of individuals indexed before 2010 was 18% ( n = 207 137); 2010‐2015, 31% (361 175); and after 2015, 52% (609 095). Overall, 184 420 (15.7%) developed CVRD, of which cardiorenal disease was most frequently the first disease to develop (59.7%), consisting of 23.0% HF and 36.7% CKD, and more common than stroke (16.9%), MI (13.7%), and PAD (9.7%). The total cumulative cost for CVRD was US$1 billion, of which 59.0% was attributed to cardiorenal disease, 3‐, 5‐, and 6‐fold times greater than the costs for stroke, MI, and PAD, respectively. Conclusion: Across all nations, HF or CKD was the most frequent CVRD manifestation to develop in a low‐risk population with T2D, accounting for the highest proportion of hospital healthcare costs. These novel findings highlight the importance of cardiorenal awareness when planning healthcare.

1 April 2022 in Decision Support Systems
Verified
Journal Article
Open access
NSNaomi Simumba
Naomi Simumba
SOSuguru Okami
Suguru Okami
AKAkira Kodaka
Akira Kodaka
NKNaohiko Kohtake
Naohiko Kohtake

1 November 2020 in Kidney Medicine
Verified
Journal Article
Open access
EKEiichiro Kanda
Eiichiro Kanda
NKNaoki Kashihara
Naoki Kashihara
SKShun Kohsaka
Shun Kohsaka
SOSuguru Okami
Suguru Okami
TYToshitaka Yajima
Toshitaka Yajima
Hyperkalemia is a common electrolyte abnormality of chronic kidney disease and heart failure associated with increased mortality and morbidity. We aimed to assess the long-term economic burden of hyperkalemia. Observational cohort study using a Japanese nationwide hospital claims database (April 1, 2008, to September 30, 2018). : Patients 18 years or older with at least 1 serum potassium value (N = 1,208,894). Hyperkalemia defined with the presence of at least 2 serum potassium values ≥ 5.1 mmol/L. Direct health care costs and resource use in patients with hyperkalemia within and after 12 months from first hyperkalemia episodes. Health care costs and resource use were compared with propensity score–matched or nonmatched normokalemic controls. Multivariable regression analysis was performed to examine factors associated with health care costs. 27,534 patients with hyperkalemia and 233,098 normokalemic controls were studied. Mean ± SD age was 73±13 years in patients with hyperkalemia; among them, 59% and 35% had chronic kidney disease and heart failure, respectively. In the propensity score–matched cohort (n = 5,859 in each group), average numbers of hospitalizations per patient per year in patients with hyperkalemia within and after 12 months were 1.2 and 1.6 times higher, respectively, compared with those in patients with normokalemia. The total cost per patient in patients with hyperkalemia was higher than for controls, with mean differences of $8,611 (95% CI, $8,046-$9,175) within 12 months and $5,150 (95% CI, $4,733-$5,566) after 12 months. The number of repeat hyperkalemic episodes was the factor with the strongest association with long-term health care costs, whereas severity of hyperkalemia was not associated. This study used secondary data; therefore, residual confounders may not be fully excluded. Hyperkalemia was associated with significant long-term economic burden with frequent hospitalizations due to recurrent episodes, indicating the importance of hyperkalemia treatment for the sake of reducing health economic burdens and clinical complications.